Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study
Journal of Clinical Immunology · 2024
DOI: 10.1007/s10875-024-01769-8 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Immunology, 2024. Verfasst von Arye Rubinstein und 10 weiteren Autor:innen. Beteiligte Einrichtung: Albert Einstein College of Medicine and Montefiore Hospital, Bronx, NY, USA. Hauptthemen laut MEDLINE: Hyaluronoglucosaminidase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Facilitated subcutaneous immunoglobulin (fSCIG) 10% is an immunoglobulin replacement therapy that utilizes recombinant human hyaluronidase (rHuPH20) to enhance immunoglobulin dispersion and absorption, allowing for longer treatment intervals similar to intravenous immunoglobulin (up to once monthly). fSCIG 10% is indicated in the USA for treating adults and children aged ≥ 2 years with primary immunodeficiency diseases (PIDs). This prospective, non-interventional, open-label, multicenter, post-authorization safety study (NCT02593188) was conducted in the USA from November 2015 to October 2021 to assess the long-term safety of fSCIG 10% in routine clinical practice. Patients with PIDs aged ≥ 16 years who were prescribed and/or had started fSCIG 10% treatment were enrolled. In total, 253 patients were enrolled and included (full analysis set). Participants received fSCIG 10% treatment for a median (interquartile range) of 10.0 (3.5–11.8) months, with the majority of infusions administered every 4 weeks (54.4% [1197/2201 infusions]) and at home (62.6% [1395/2230 infusions]). Overall, 98.5% of infusions were administered without rate reduction, interruption, or discontinuation due to adverse events (AEs). Treatment-related, non-serious AEs were experienced by 52 patients (20.6%, 284 events). Two patients (0.8%) each experienced one treatment-related serious AE (aseptic meningitis and deep vein thrombosis). Development of antibodies against rHuPH20 was uncommon; 14/196 patients (7.1%) tested positive for binding antibodies (titer ≥ 1:160) with no neutralizing antibodies detected. There was no relationship between anti-rHuPH20 antibody positivity and the occurrence of treatment-related serious or non-serious AEs. Long-term, repeated self-administration of fSCIG 10% was well tolerated in US clinical practice by patients with PIDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Albert Einstein College of Medicine and Montefiore Hospital, Bronx, NY, USA.
- Allergy Immunology Medical Center, Redlands, CA, USA.
- Optimed Research, Columbus, OH, USA.
- Duke University, Durham, NC, USA.
- Allergy Partners of North Texas Research, Dallas, TX, USA.
- University of California at Irvine, Irvine, CA, USA.
Zitieren
APA
Rubinstein, A., Mabudian, M., McNeil, D., Patel, N. C., Wasserman, R. L., Gupta, S., Carrasco, P., Chen, J., Garcia, E., Nagy, A., & Yel, L. (2024). Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-024-01769-8
Vancouver
Rubinstein A, Mabudian M, McNeil D, Patel NC, Wasserman RL, Gupta S, et al. Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study. Journal of Clinical Immunology. 2024. doi:10.1007/s10875-024-01769-8
BibTeX
@article{Rubinstein2024,
author = {Rubinstein, Arye and Mabudian, Mohsen and McNeil, Donald and Patel, Niraj C and Wasserman, Richard L and Gupta, Sudhir and Carrasco, Paz and Chen, Jie and Garcia, Enrique and Nagy, Andras and Yel, Leman},
title = {Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study},
journal = {Journal of Clinical Immunology},
year = {2024},
doi = {10.1007/s10875-024-01769-8}
}
EUVIMED